The Pricing and Reimbursement Environment for Neurology Drugs

Introduction:

Neurological disorders will impose a growing social and financial burden on the major pharmaceutical markets as the elderly population in these countries increases steadily. Governments and other payers recognize the pressing need to tackle these diseases, but they also have to control the relentless growth of healthcare expenditures. In an increasingly cost-conscious reimbursement climate, the pharmaceutical industry must clearly demonstrate the value of neurology drugs.

Get the Answers You Need to Shape Your Strategy:

• Health technology assessment will increasingly influence coverage of neurology drugs in most markets in the future. What changes are likely in Europe? How will government support for comparative effectiveness research impact the U.S. market?
• The United States has the highest overall prices of any of the major pharmaceutical markets, but prices for neurology drugs vary widely from country to country. How do European and Japanese prices for bestselling neurology drugs compare with prices in the United States? Which drugs in this therapeutic area are more expensive in Europe and Japan than in the United States?
• European reimbursement authorities limit access to high-priced neurology drugs. Which agents are key targets for reimbursement restrictions in Europe? What role do health technology assessment bodies play in regulating the use of drugs in this therapeutic area?
• The Japanese government has not employed the types of cost-containment measures used in the United States and Europe. What is the government considering with regard to the regular price revision process? What are the prospects for long-listed drugs subject to generics competition?

Scope:

• International price comparisons for neurology drugs: Alzheimer's disease therapies; Parkinson's disease therapies; multiple sclerosis therapies; antiepileptics; migraine therapies.
• Reimbursement environment in the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan: general environment; Alzheimer's disease therapies; Parkinson's disease therapies; multiple sclerosis therapies; antiepileptics; migraine therapies.
• Outlook and implications for the pharmaceutical industry: impact of healthcare reform in the United States; cost-containment trends; prospects for biosimilars; increasing use of health technology assessment; innovative approaches to pricing and reimbursement.

Please note, the PDF e-mail from publisher version of this report is for a global site license.